BNET Industries
Market Cap:$117.6B
Last Fiscal Year Sales:$32.4B
- Public
- CH
Dow Jones Description
Roche's focus is health. Roche Holding Ltd. (OTC: RHHVF (ADR) Swiss) was founded in 1896 and is headquartered in Basel, Switzerland. The company operates in two segments, which are pharmaceuticals and diagnostics. Its drugs include Accutane, Herceptin, Invirase, Rituxan, Rocephin, Tamiflu, and Xenical, among others. It owns 60% of Genentech and 51% of Chugai Pharmaceutical. The company has annual revenue of about $27 billion and employs about 68,000 people. In 2005, it sold its consumer healthcare division to Bayer, allowing it to focus on core business.In July 2005 the company acquired GlycArt Biotechnology AG, a privately owned Swiss biotech company that provides technology for enhancing the efficacy of antibodies will further strengthen Roche's expertise in therapeutic antibody research and development.
Chief Executive Officer
Severin SchwanNumber of Employees 80,080
Peer Companies
NAICS Code In-Vitro Diagnostic Substance Manufacturing: 325413
Recent Events
-
EpiVax signs deal with drug giant Roche
-
2nd UPDATE:Roche Says Diabetes Drug Better Than Merck Januvia
-
Roche announces late-stage trial for heart drug
-
AstraZeneca lifted to buy, Roche cut to hold: RBS
-
BioCryst faces tight competition in H1N1 flu drug market
-
Alnylam Pharmaceuticals signs co-development agreement with Roche for RNAi therapeutics
-
UPDATE: Roche's New Diabetes Drug Works Better Than Byetta
-
Sumitomo Mitsui Sues Credit Suisse Over Capmark Loan Repayment
-
Roche raises Tamiflu's sales outlook
-
SurModics enters license and development agreement with Roche and Genentech
-
BRIEF-Roche launches new MagNA pure 96 system
-
Roche U.S. cancer drug trial enrollment suspended
-
Vivus CEO Ready To Roll Up Sleeves In Finding Qnexa Partner
-
ImmunoCellular in research and license option deal with Roche
-
UPDATE 1-Roche names Genentech's Soriot new drugs chief
-
Glance-Europe Factors-Shares set to rise, tracking Asia
-
Roche Holding names Soriot as head of pharma
News & Analysis
Filter by
company and pharmaceutical company and roche holding ag - All News and Analysis
Drugmaker ready for outbreak.(Spotlight: RIMS 2007 Trends & Developments)(F. Hoffmann-La Roche Ltd. preparations for a deadly pandemic)(Brief article)
Byline: Gloria Gonzalez Being the manufacturer of the No. 1 prescribed influenza medication has put pharmaceutical company F. Hoffmann-La Roche Ltd. at the forefront of preparations for a potentially deadly pandemic. As part of its pandemic prep Byline: Gloria Gonzalez ...
Roche gets Chugai greenlight...and opens South African plant. (Business in Brief).(Brief Article)
Roche reports that shareholders of the Japanese pharmaceutical company Chugai voted in favor of the companies' merger, with over 90 percent voting for the ... Roche reports that shareholders of the Japanese pharmaceutical company Chugai voted in favor of the companies' merger, with over...
Leading Drug Makers Post Good 2nd Quarter Growth.
Most industry majors meet or beat analyst expectation. LEADING DRUG MANUFACTURERS posted higher growth in the second quarter, either meeting or beating analysts' expectations. The strong second quarter results stem primarily from healthy pharm Most industry majors meet or...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Severin Schwan | Chief Executive Officer |
| William M. Burns | CEO, Roche Pharma |
| Erich Hunziker | CFO |
| Jonathan K.C. Knowles | Managing Director, Global Pharmaceutical Research |
| Roche Rolf D Schl | Managing Director, Partner |
| Rolf D Schl | Managing Director, Partner |
| Andres Greuter | Compliance Officer |
| Beatrice Weder | |
| Beatrice Weder di Mauro | |
| Berufliche Laufbahn | |
| Burkhard G Piper | |
| Dr Roche Severin Schwan | |
| Editiones Roche | |
| Eduard E Holdener | |
| Emil Frey Dir | |
| Ernst Peter Fischer | |
| Fr U here Mandate | |
| Fritz Gerber | |
| Gottlieb A. Keller | Secretary & Head, Corp Services, HR |
| Heino von Prondzynski | |
| Ian Massey | |
| James Childress | |
| Leiter der | |
| Leiter Therapiebereichs Des | |
| Lydia Mez | |
| Mina Michal | |
| Myrl Weinberg | |
| Okonomin beim Internationalen WAhrungsfonds | |
| Osamu Nagayama | |
| Peter Brabeck | |
| Ph D in Genetics | |
| Ph D in Genetik | |
| Pierre Jaccoud | |
| Prof Dr Roche Bruno Gehrig | |
| Robert B. Stein | |
| Robert Spreng | |
| Roche Burkhard G Piper | |
| Roche Genetics | |
| Roche Pierre Jaccoud | |
| Roche Sitemap | |
| Seite drucken | |
| Susan Jebb | |
| Werner Schreiber | |
| Ysbrand Portman |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Dr Roche Gottlieb Keller | Chairman |
| Andre Hoffman | Board of Directors |
| Andre Hoffmann | Vice-Chairman of the Board |
| Andreas Oeri | Board of Directors |
| Brouno Gehring | Vice Chairman |
| Bruno Gehrig | Vice Chairman |
| DeAnne S. Julius | Board of Directors |
| F Hoffmann | Vice chairman |
| Horst Teltschik | Board of Directors |
| John Irving Bell | Board of Directors |
| Lodewijk J.R. De Vink | Board of Directors |
| Peter Brabeck-Letmathe | Board of Directors |
| Roche Rolf H A nggi | Vice-Chairman |
| Rolf Haenggi | Board of Directors |
| Rolf Hanggi | Board of Directors |
| Walter Frey | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Chief Executive Officer | Current |
| University of Innsbruck | Degree, Economics | Former |
| University of Innsbruck | Doctorate in Law | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | CEO, Roche Pharma | Current |
| Roche Products (Proprietary) Limited | President | Current |
| Chugai Pharmaceutical Co., Ltd. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | CFO | Current |
| F. Hoffmann-La Roche Ltd. | CFO | Current |
| Chugai Pharmaceutical Co., Ltd. | Board of Directors | Current |
| Genentech, Inc. | Board of Directors | Current |
| Holcim Ltd. | Board of Directors | Current |
| Diethelm Keller Holding Ltd. | Chief Executive Officer | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Managing Director, Global Pharmaceutical Research | Current |
| Genentech, Inc. | Head, Global Research | Current |
| Genentech, Inc. | Board of Directors | Current |
| Chugai Pharmaceutical Co., Ltd. | Board of Directors | Current |
| University of East Anglia | Honours Degree in Molecular Genetics | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Managing Director, Partner | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Managing Director, Partner | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Compliance Officer | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current | |
| Boehringer Mannheim | CEO | Former |
| Boehringer Mannheim | Sales Managers Industrial | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current | |
| The University of Kansas | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current | |
| University of Bern | Lawyer LL | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Diagnostics Corporation | Secretary | Current |
| Roche Holding Ltd. | Secretary & Head, Corp Services, HR | Current |
| Roche Holding Ltd. | Board of Directors | Current |
| Roche Diagnostics Corporation | Secretary | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current | |
| Alcon, Inc. | Vice Chairman | Current |
| Nestle S.A. | CEO | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current | |
| University of Bern | Doctorate in economics (Dr | Former |
Dr. Robert Stein currently serves on the President's Board of Advisors for Science and Innovation for the University of California , is a Member of the Board of Directors of Archemix, and Scientific Advisor to Takeda San Diego. Bob served as the Site President of the Palo Alto , California site of F. Hoffmann-La Roche Ltd from 2003 to 2006. Prior to joining Roche, Bob was the President and Chief Scientific Officer of Incyte Corporation from 2001 to 2003. Bob also served in various roles for Merck & Co., Ligand Pharmaceuticals Inc., the DuPont Merck Pharmaceutical Company and DuPont Pharmaceuticals Company, where he was Executive Vice President of Research and Preclinical Development from 1990 to 1996. Bob received degrees in biology and chemistry from Indiana University , where he was Phi Beta Kappa, and an M.D. and a Ph.D. in physiology and pharmacology from Duke University . Bob completed residency training and is board certified in anatomic and clinical pathology.
| Organization | Position | Status |
|---|---|---|
| Kinemed, Inc | Chief Executive Officer | Current |
| Roche Holding Ltd. | Current | |
| Archemix Corp | Board of Directors | Current |
| F. Hoffmann-La Roche Ltd. | Site President | Former |
| Incyte Corporation | President | Former |
| Ligand Pharmaceuticals Incorporated | chief | Former |
| Incyte Corporation | Chief Scientific Officer | Former |
| Ligand Pharmaceuticals Incorporated | senior vice president | Former |
| Roche | Former | |
| Duke University | M.D. | Former |
| Indiana University | Degrees In Biology | Former |
| Duke University | Degrees In Biology | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current | |
| Boehringer Mannheim | CEO | Former |
| Boehringer Mannheim | Regional Sales Manager | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current | |
| Rs-R | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current | |
| Alcon, Inc. | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Chairman | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Living Planet Management Company | Chairman | Current |
| Roche Holding Ltd. | Vice-Chairman of the Board | Current |
| Givaudan S.A. | Vice Chairman | Current |
| Roche Holding Ltd. | Member | Current |
| Nestle Uk Ltd | Brand Manager | Former |
| Givaudan S.A. | Board of Directors | Former |
| INSEAD | Masters of Business Administration | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Board of Directors | Current |
| University of Basel | Medical Studies | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Vice Chairman | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Vice Chairman | Current |
| Roche Holding Ltd. | Board of Directors | Current |
| University of Bern | Doctorate in economics (Dr | Former |
| Organization | Position | Status |
|---|---|---|
| The Royal Institute of International Affairs | Chairman | Current |
| Roche Holding Ltd. | Board of Directors | Current |
| BP plc | Board of Directors | Current |
| University of California | Ph.D In Economics | Former |
| Iowa State University | Ph.D | Former |
| Iowa State University | Bsc | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Vice chairman | Current |
| Roche Holding Ltd. | Chief Executive Officer | Former |
| Diageo plc | Board member | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Board of Directors | Current |
Peter Brabeck-Letmathe has been a member of the Board since 1997 and served as Vice-Chairman from 2000 to 2005 and since 2008. Since 2008 he has also served on the Chairman's and Governance Committee and the Compensation Committee. On both of these committees he has already served in the past, namely from 2003 to 2005 and 2000 to 2005, respectively. His term as a member of the Board expires at the AGM in 2011. The Board has determined him to be independent under the Group’s independence standards. Peter Brabeck-Letmathe studied Economics at the University of World Trade in Vienna. After graduation in 1968, he joined Nestlé’s sales operations in Austria. His career at Nestlé includes a variety of assignments in several European countries as well as in Latin America. Since 1987, he has been based at Nestlé’s headquarters in Vevey. Since 1997, Mr. Brabeck-Letmathe has served as the Chief Executive Officer of Nestlé and as a member of Nestlé’s Board of Directors. In 2005, Mr. Brabeck-Letmathe was appointed Chairman of the Board of Directors of Nestlé. As of April 10, 2008 he has retired from his function as Chief Executive Officer of Nestlé. Mr. Brabeck is a member of the Boards of Directors of L’Oréal SA, Paris (since 1997) and Roche Holding SA, Basel (since 2000). He is also a member of the Foundation Board of the World Economic Forum and a member of the European Round Table of Industrialists.
| Organization | Position | Status |
|---|---|---|
| Credit Suisse Group | Vice Chairman | Current |
| Winterthur Schweizerische Versicherungs Gesellschaft | Vice Chairman | Current |
| Credit Suisse Group | Board of Directors | Current |
| Nestle S.A. | Board of Directors | Current |
| L'Oreal S.A. | Board of Directors | Current |
| Roche Holding Ltd. | Board of Directors | Current |
| World Economic Forum | Member, Foundation Board | Current |
| Nestle S.A. | Chief Executive Officer | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Vice-Chairman | Current |
| Zurich Insurance Company | Deputy Chief Executive Officer | Former |
| Zurich Insurance | Member | Former |
| Zurich Insurance Company | Member | Former |
| Nestle S.A. | Vice-Chairman | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Board of Directors | Current |
| Roche Holding Ltd. | Vice Chairman | Current |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Board of Directors | Current |
| Nestle S.A. | Second Vice Chairman | Current |
| Nestle S.A. | Second Vice Chairman | Current |
| Zurich Insurance Company | Deputy Chief Executive Officer | Former |
| Zurich Insurance Company | Member | Former |
| Zurich Insurance | Member | Former |
| Nestle S.A. | Vice-Chairman | Former |
| Organization | Position | Status |
|---|---|---|
| Roche Holding Ltd. | Board of Directors | Current |
Executive News
-
Week of Sept. 7, 2009: Facet Rejects Biogen Idec's Proposal; Roche Announces Management Changes; More...
-
Roche Names Pharma Chief
-
Roche Announces New Corporate Executive Committee
-
Roche moving Clark to CEO of Genentech
-
KineMed to Collaborate with Bristol-Myers Squibb
-
Cancer Drugs: Herceptin News and More
-
Cancer Drugs: News from ASCO
-
KineMed, Inc. Enters Into Collaboration With Bristol-Myers Squibb Company (BMY) (JOBS)
-
KineMed Enters Into Collaboration With Bristol-Myers Squibb
-
KineMed Enters Into Collaboration With Bristol-Myers Squibb
-
Roche to Present Major Advances With Targeted Cancer Medicines at ASCO
-
Roche Sees Herceptin Growth As Stomach Cancer Drug
-
Roche provides additional donation of 5.65 million packs of Tamiflu to World Health Organization
-
Roche Donates Tamiflu to WHO
| Volume | 680,218 |
| Shares Outstanding | 2.8B |
| Market Cap | 117.6B |
| Year High | 42.30 |
| Year Low | 26.010 |
| Earnings Per Share | 2.37 |
| P/E Ratio | 17.6582 |
| Dividend | 0.6652 |
| Yield | 1.5895 |
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- Why J&J's Stelara Launch Should Target Dermatologists First 3 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes
